Alzheimer Drug Fails To Slow Decline In A Trial

An experimental Alzheimer drug from Roche ROG.S and AC Immune ACIU.O failed to slow cognitive and functional decline in a trial.

An experimental Alzheimer drug from Roche ROG.S and AC Immune ACIU.O failed to slow cognitive and functional decline in a trial, the Swiss companies said on Wednesday, in a fresh setback to efforts to fight the fatal dementia-causing disease.

interesting reading:  Manipulate Genes Of The Bacteria That Live Around Plants Lead To Better Crops

AC Immune boss Andrea Pfeifer described the results of the trial of semorinemab as “surprising and disappointing”.

The drug targets “tau” proteins believed to play a role in Alzheimer’s and offers an alternative to treatments aiming to fight amyloid beta peptides in the brain.

The outcome of the Phase 2 trial – in patients with an early stage of Alzheimer’s – means the failure rate for drugs aiming to fight the brain-wasting illness, which afflicts tens of millions of people worldwide, remains at nearly 100%.

“We believe the full data analysis of this first-of-its-kind study will yield information about this promising target that will advance our understanding and inform future efforts,” Pfeifer said.

interesting reading:  Samsung's Neo QLED TVs Are Packed With Futuristic-Sounding Tech

So far, Alzheimer’s drugs have nearly always stumbled in trials, though the U.S. Food and Drug Administration is now reviewing experimental treatment aducanumab from Biogen BIIB.O and Japan’s Eisai 4523.T, marking the first Alzheimer’s drug application in 17 years to be reviewed by the agency.

Aducanumab targets amyloid beta peptides, but nearly all similar drugs have failed, so far, including prospective medicines from Roche and AC Immune. Consequently, the companies were hoping anti-tau medicines like semorinemab would yield better results and said this result was a disappointment.

interesting reading:  US Gov’t To Force African Countries To Loosen Ban On Plastics

“We believe these data will contribute to the scientific understanding of the role of tau in this complex and difficult-to-treat disease,” said Rachelle Doody, head of Roche’s neurodegeneration operation.

Roche and AC Immune have other anti-tau medicines in development, along with many other companies, including Eli Lilly LLY.N, Biogen and Johnson & Johnson JNJ.N.

The article is originally published at Reuters

Leave a Reply

Your email address will not be published. Required fields are marked *

Captcha loading...